Patents by Inventor Robert G. Aslanian

Robert G. Aslanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzimidazolone histamine Hantagonists
    Patent number: 7220735
    Abstract: Disclosed are novel compounds of the formula wherein R1 is benzimidazolone derivative, M1 and M2 are optionally substituted carbon or nitrogen, R2 includes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification, and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an H1 receptor antagonist.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: May 22, 2007
    Assignee: Schering Corporation
    Inventors: Pauline C. Ting, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom, Qingbei Zeng
  • Benzimidazole derivatives useful as histamine H3 antagonists
    Patent number: 7105505
    Abstract: Disclosed are novel compounds of the formula wherein R1 is optionally substituted benzimidazolyl or a derivative thereof; R2 is optionally substituted aryl or heteroaryl; M1 and M2 are C(R3) or N; and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an H1 receptor antagonist.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: September 12, 2006
    Assignee: Schering Corporation
    Inventors: Qingbei Zeng, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Joseph A. Kozlowski, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom
  • Indole derivatives useful as histamine H3 antagonists
    Patent number: 6951871
    Abstract: Disclosed are novel compounds of the formula wherein M1 is CH or N and M2 is C(R3) or N; R1 is optionally substituted indolyl or an aza derivative thereof; R2 is optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I in combination with a H1 receptor antagonist.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: October 4, 2005
    Assignee: Schering Corporation
    Inventors: Robert G. Aslanian, Michael Y. Berlin, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum
  • Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders
    Patent number: 6906081
    Abstract: This invention relates to a method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H3 receptor antagonist/m2 muscarinic antagonist, or a combination of a histamine H3 receptor antagonist and a m2 muscarinic antagonist.
    Type: Grant
    Filed: February 6, 2002
    Date of Patent: June 14, 2005
    Assignee: Schering Corporation
    Inventors: John A. Hey, Robert G. Aslanian
  • Piperidine compounds
    Patent number: 6849621
    Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H. receptor antagonist.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: February 1, 2005
    Assignees: Schering Corporation, Pharmacopeia Drug Discovery, Inc.
    Inventors: Stuart B. Rosenblum, Qingbei Zeng, Mwangi Wa Mutahi, Robert G. Aslanian, Pauline C. Ting, Neng-Yang Shih, Daniel M. Solomon, Jianhua Cao, Henry A. Vaccaro, Kevin D. McCormick, John J. Baldwin, Ge Li
  • Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
    Patent number: 6762186
    Abstract: The present invention discloses novel substituted imidazole compounds which have H3 receptor antagonist or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, nasal congestion, inflammatory and CNS-related diseases and others.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: July 13, 2004
    Assignee: Schering Corporation
    Inventors: Neng-Yang Shih, Robert G. Aslanian, Daniel M. Solomon, Stuart B. Rosenblum, Mwangi Wa Mutahi, Tom G. Wing, Kevin D. McCormick, John J. Piwinski, Ronald Wolin
  • Benzimidazole derivatives useful as histamine H3 antagonists
    Publication number: 20040097483
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: April 16, 2003
    Publication date: May 20, 2004
    Inventors: Qingbei Zeng, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Joseph A. Kozlowski, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom
  • Novel non-imidazole compounds
    Publication number: 20040097513
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: October 31, 2003
    Publication date: May 20, 2004
    Inventors: Robert G. Aslanian, Neng-Yang Shih, Pauline C. Ting, Michael Y. Berlin, Stuart B. Rosenblum, Kevin D. McCormick, Wing C. Tom, Christopher W. Boyce, Pietro Mangiaracina, Mwangi W. Mutahi, John J. Piwinski
  • Non-imidazole compounds
    Patent number: 6720328
    Abstract: Disclosed are novel compounds of the formula In Formula I, M1 is carbon, M2, M3 and M4 are carbon or nitrogen and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: April 13, 2004
    Assignee: Schering Corporation
    Inventors: Robert G. Aslanian, Neng-Yang Shih, Pauline C. Ting, Michael Y. Berlin, Stuart B. Rosenblum, Kevin D. McCormick, Wing C. Tom, Christopher W. Boyce, Pietro Mangiaracina, Mwangi W. Mutahi, John J. Piwinski
  • Benzimidazolone histamine H3 antagonists
    Publication number: 20040048843
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: April 16, 2003
    Publication date: March 11, 2004
    Applicant: Schering Corporation
    Inventors: Pauline C. Ting, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom, Qingbei Zeng
  • Indole derivatives useful as histamine H3 antagonists
    Publication number: 20040019099
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: June 20, 2003
    Publication date: January 29, 2004
    Applicant: Schering Corporation
    Inventors: Robert G. Aslanian, Michael Y. Berlin, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum
  • Novel non-imidazole compounds
    Publication number: 20030109564
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: March 11, 2002
    Publication date: June 12, 2003
    Applicant: Schering Corporation
    Inventors: Stuart B. Rosenblum, Qingbei Zeng, Mwangi Wa Mutahi, Robert G. Aslanian, Pauline C. Ting, Neng-Yang Shih, Daniel M. Solomon, Jianhua Cao, Henry A. Vaccaro, Kevin D. McCormick, John J. Baldwin, Ge Li
  • Novel non-imidazole compounds
    Publication number: 20030045519
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: October 15, 2001
    Publication date: March 6, 2003
    Inventors: Robert G. Aslanian, Neng-Yang Shih, Pauline C. Ting, Michael Y. Berlin, Stuart B. Rosenblum, Kevin D. McCormick, Wing C. Tom, Christopher W. Boyce, Pietro Mangiaracina, Mwangi W. Mutahi, John J. Piwinski
  • Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
    Patent number: 6528522
    Abstract: The present invention discloses novel substituted imidazole compounds which have H3 receptor antagonist activity or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, congestion, inflammatory and CNS-related diseases and others.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: March 4, 2003
    Assignee: Schering Corporation
    Inventors: Neng-Yang Shih, Robert G. Aslanian, John J. Piwinski, Andrew T. Lupo, Jr., Adriano Afonso
  • Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
    Patent number: 6518287
    Abstract: The present invention discloses novel substituted imidazole compounds which have either or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, inflammatory and CNS-related diseases and others.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: February 11, 2003
    Assignee: Schering Corporation
    Inventors: Robert G. Aslanian, Stuart Rosenblum, Mwangi Wa Mutahi, Neng-Yang Shih, John J. Piwinski
  • Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders
    Publication number: 20020151565
    Abstract: This invention relates to a method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H3 receptor antagonist/m2 muscarinic antagonist, or a combination of a histamine H3 receptor antagonist and a m2 muscarinic antagonist.
    Type: Application
    Filed: February 6, 2002
    Publication date: October 17, 2002
    Applicant: Schering Corporation
    Inventors: John A. Hey, Robert G. Aslanian
  • Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
    Publication number: 20020103235
    Abstract: The present invention discloses novel substituted imidazole compounds which have either or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, inflammatory and CNS-related diseases and others.
    Type: Application
    Filed: September 18, 2001
    Publication date: August 1, 2002
    Inventors: Robert G. Aslanian, Stuart B. Rosenblum, Mwangi Wa Mutahi, Neng-Yang Shih, John J. Piwinski
  • Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
    Publication number: 20020082278
    Abstract: The present invention discloses novel substituted imidazole compounds which have H3 receptor antagonist or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, nasal congestion, inflammatory and CNS-related diseases and others.
    Type: Application
    Filed: September 18, 2001
    Publication date: June 27, 2002
    Inventors: Neng-Yang Shih, Robert G. Aslanian, Daniel M. Solomon, Stuart B. Rosenblum, Mwangi Wa Mutahi, Wing C. Tom, Kevin D. Mc Cormick, John J. Piwinski, Ronald Wolin
  • Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
    Publication number: 20020082272
    Abstract: The present invention discloses novel substituted imidazole compounds which have H3 receptor antagonist activity or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, congestion, inflammatory and CNS-related diseases and others.
    Type: Application
    Filed: September 18, 2001
    Publication date: June 27, 2002
    Inventors: Neng-Yang Shih, Robert G. Aslanian, John J. Piwinski, Andrew T. Lupo, Adriano Afonso
  • Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
    Patent number: 6211182
    Abstract: This invention discloses novel imidazoles substituted with a six or seven membered heterocyclic ring which contains two nitrogen atoms as part of the heterocyclic ring structure. These compounds have excellent histamine-H3 receptor antagonist activity. Also disclosed are methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma)—i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypomotility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimer's Disease, schizophrenia, and migraine).
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: April 3, 2001
    Assignee: Schering Corporation
    Inventors: Wayne Vaccaro, John J. Piwinski, Wing C. Tom, Daniel M. Solomon, Robert G. Aslanian